Neumora Therapeutics, Inc. announced the initiation of a Phase 1 single ascending dose /multiple ascending dose study evaluating NMRA-266 in healthy adult participants. NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. Neumora believes that as a selective M4 receptor-positive allosteric modulator, NMRA-266 has the potential to deliver antipsychotic efficacy, while minimizing the side effects associated with current antipsychotics and other non-selective muscarinic agonists.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.68 USD | +1.04% | +0.96% | -44.22% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.22% | 1.53B | |
+28.67% | 49.18B | |
+0.85% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.38% | 26.09B | |
-22.38% | 18.71B | |
+8.00% | 13.26B | |
+32.17% | 12.32B | |
-0.42% | 11.99B |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.
- Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study